These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20808270)

  • 21. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
    Choi BB; Kim SH
    Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.
    Park S; Yoon JH; Sohn J; Park HS; Moon HJ; Kim MJ; Kim EK; Kim SI; Park BW
    PLoS One; 2016; 11(2):e0149347. PubMed ID: 26866475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy.
    Um E; Kang JW; Lee S; Kim HJ; Yoon TI; Sohn G; Chung IY; Kim J; Lee JW; Son BH; Ahn SH; Ko BS
    Clin Breast Cancer; 2018 Oct; 18(5):e1087-e1091. PubMed ID: 29703689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy.
    Williams M; Eatrides J; Kim J; Talwar H; Esposito N; Szabunio M; Ismail-Khan R; Kiluk J; Lee M; Laronga C; Khakpour N
    Am J Surg; 2013 Oct; 206(4):567-73. PubMed ID: 23809673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.
    Guarneri V; Pecchi A; Piacentini F; Barbieri E; Dieci MV; Ficarra G; Tazzioli G; Frassoldati A; Battista R; Canossi B; Mauri C; D'Amico R; Conte P; Torricelli P
    Ann Surg Oncol; 2011 Aug; 18(8):2150-7. PubMed ID: 21301969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor.
    An YY; Kim SH; Kang BJ
    World J Surg Oncol; 2017 Nov; 15(1):198. PubMed ID: 29110671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [MRI evaluation of primary chemotherapy response in breast cancer].
    Vénat-Bouvet L; Desfougères M; Aubard Y; Mollard J; Fermeaux V; Genet D; Labourey JL; Martin J; Lebrun-Ly V; Maubon A; Tubiana-Mathieu N
    Bull Cancer; 2004 Sep; 91(9):721-8. PubMed ID: 15544998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy.
    Demartini WB; Lehman CD; Peacock S; Russell MT
    Acad Radiol; 2005 Jul; 12(7):806-14. PubMed ID: 16039534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective trial of breast MRI versus 2D and 3D ultrasound for evaluation of response to neoadjuvant chemotherapy.
    Lee MC; Gonzalez SJ; Lin H; Zhao X; Kiluk JV; Laronga C; Mooney B
    Ann Surg Oncol; 2015 Sep; 22(9):2888-94. PubMed ID: 25589151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of axillary nodal imaging by magnetic resonance imaging based on breast cancer subtype after neoadjuvant chemotherapy.
    Steiman J; Soran A; McAuliffe P; Diego E; Bonaventura M; Johnson R; Ahrendt G; McGuire K
    J Surg Res; 2016 Jul; 204(1):237-41. PubMed ID: 27451892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contrast-Enhanced Mammography (CEM) for Detecting Residual Disease after Neoadjuvant Chemotherapy: A Comparison with Breast Magnetic Resonance Imaging (MRI).
    Barra FR; Sobrinho AB; Barra RR; Magalhães MT; Aguiar LR; de Albuquerque GFL; Costa RP; Farage L; Pratesi R
    Biomed Res Int; 2018; 2018():8531916. PubMed ID: 30533440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging.
    Abraham DC; Jones RC; Jones SE; Cheek JH; Peters GN; Knox SM; Grant MD; Hampe DW; Savino DA; Harms SE
    Cancer; 1996 Jul; 78(1):91-100. PubMed ID: 8646731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy.
    Akazawa K; Tamaki Y; Taguchi T; Tanji Y; Miyoshi Y; Kim SJ; Ueda S; Yanagisawa T; Sato Y; Tamura S; Noguchi S
    Breast J; 2006; 12(2):130-7. PubMed ID: 16509837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI.
    Balu-Maestro C; Chapellier C; Bleuse A; Chanalet I; Chauvel C; Largillier R
    Breast Cancer Res Treat; 2002 Mar; 72(2):145-52. PubMed ID: 12038705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
    AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.
    Peintinger F; Kuerer HM; Anderson K; Boughey JC; Meric-Bernstam F; Singletary SE; Hunt KK; Whitman GJ; Stephens T; Buzdar AU; Green MC; Symmans WF
    Ann Surg Oncol; 2006 Nov; 13(11):1443-9. PubMed ID: 17028770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
    Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
    Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Chen X; Moore MO; Lehman CD; Mankoff DA; Lawton TJ; Peacock S; Schubert EK; Livingston RB
    Acad Radiol; 2004 Oct; 11(10):1115-24. PubMed ID: 15530804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.